Patients with chronic migraine who used GLP-1 receptor agonists such as liraglutide to treat obesity or diabetes had fewer emergency department visits compared to patients taking topiramate.[1] In a 12-week prospective study of 31 adult participants, liraglutide was administered subcutaneously with a dose titration from 0.6 mg to 3 mg daily to minimize gastrointestinal side effects.[1][2] The number of days with migraines dropped from an average of 20 to about 11 days per month.[2] Many participants experienced a clinically significant reduction in headache frequency and migraine burden.[1] The study is the first prospective investigation of GLP-1 agonists in patients with chronic migraine and obesity.[1] Liraglutide probably reduces intracranial pressure and suppresses the release of the peptide CGRP, a key mediator of migraines.[1][2]